RecruitingNCT07276997
Icalcaprant for depression in adults
About this title
Read the official source — NCT07276997Researchers are comparing Icalcaprant and placebo to find out how the approaches affect depression symptoms in people with depression.
Medication studyAges 18–65United States
Understand this study
What is this study about?
Researchers are comparing Icalcaprant and placebo to find out how the approaches affect depression symptoms in people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Dothan and 32 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 18, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 195
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07276997
- Official title
Show the full official title
A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Major Depressive Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Dothan · Phoenix · Little Rock
27 more locations
- Anaheim
- Imperial
- Lemon Grove
- Long Beach
- Sherman Oaks
- Temecula
- Walnut Creek
- Hollywood
- Jacksonville
- Miami
- Orlando
- Riverview
- Atlanta
- Norcross
- Chicago
- Warrenville
- Las Vegas
- New York
- Avon Lake
- Columbus
- Oklahoma City
- Memphis
- Austin
- Bellaire
- Richardson
- Bellevue
- Everett
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing Icalcaprant and placebo to find out how the approaches affect depression symptoms in people with depression.
Who is behind this study?
The study sponsor is AbbVie.
Does this study involve medication?
Yes. The study involves medication, including Icalcaprant and Placebo for Icalcaprant.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
